Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Galapagos NV

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, TG Therapeutics, Inc. and Galapagos NV have shown contrasting strategies in this area. From 2014 to 2023, Galapagos NV's SG&A expenses surged by over 900%, peaking in 2022. In contrast, TG Therapeutics, Inc. maintained a more stable trajectory, with expenses increasing by approximately 400% over the same period.

A Closer Look at Trends

Galapagos NV's expenses saw a dramatic rise in 2020, reaching a high in 2022, before dropping by 60% in 2023. Meanwhile, TG Therapeutics, Inc. experienced a significant spike in 2020, with a 25% increase, but managed to stabilize thereafter. These trends highlight the differing approaches to cost management, with Galapagos NV opting for aggressive expansion and TG Therapeutics, Inc. focusing on steady growth.